← Back to all trials
Recruiting
NCT05652712
A Real-World Study of Toripalimab in Chinese Patients With Lung Cancer(THUNDER Study)
Conditions: Lung Cancer
Sex: All
Ages: 18 Years – N/A
Enrollment: 200
Sponsor: Qianfoshan Hospital
Location: China
Summary
Our project is going to clarify the efficacy and safety of Toripalimab in lung cancer in the real world, and to evaluate the incidence of adverse events (AEs) of special interest during Toripalimab immunotherapy.
Eligibility Criteria
Inclusion Criteria:Age ≥ 18 years.Cytologically or histologically confirmed lung cancer.Complete clinical data.Indications for immunotherapy with Toripalimab.Exclusion Criteria:Lack of patient key data.Refusal or uncooperation with the study.
Source: ClinicalTrials.gov (NCT05652712). StuddyBuddy aggregates publicly available trial information.
